Pfizer Inc.
Real-time prices from Yahoo Finance's public feed. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Latest news
All PFE news ›Lockheed Martin Declares Fourth Quarter 2026 Dividend
Nasdaq Lockheed Martin Declares Fourth Quarter 2026 Dividend Oct 9, 2026 4:30pm EDT
Western Union Yields Nearly 15%. These 6 Dividend Stocks Could Be Headed for a Painful Cut
A 14.9% yield sounds like a windfall until you see what is propping it up. Six dividend stocks are flashing the same warning signs, and the companies shedding their best businesses may be the most dangerous of all. Quick test: a dividend…
Pfizer (PFE) Gets a Hold from UBS
UBS analyst Michael Yee maintained a Hold rating on Pfizer today and set a price target of $27.00. Yee covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Amgen, and Bristol-Myers Squibb. According to TipRanks,…
J.P. Morgan Keeps Their Hold Rating on Pfizer (PFE)
J.P. Morgan analyst Chris Schott maintained a Hold rating on Pfizer today and set a price target of $30.00. Schott covers the Healthcare sector, focusing on stocks such as Merck & Company, Bristol-Myers Squibb, and Eli Lilly & Co.…
Pfizer’s Dividend Yield Is Above 6%. Wall Street May Be Sending a Warning
Pfizer's dividend yield has climbed well above what most blue-chip drugmakers offer, and the reason behind that gap matters far more than the number itself. Pfizer (NYSE:PFE | PFE Price Prediction) pays a 6.16% dividend yield. For a…
Pardon Our Interruption
P stock has soared 147% in six months, fueled by AI demand and hyperscale growth. But does its premium valuation leave room for further gains? As you were browsing something about your browser made us think you were a bot. There are a few…
Frontline TUKYSA Maintenance Approval Could Be A Game Changer For Pfizer (PFE)
Pfizer recently received U.S. FDA approval for TUKYSA (tucatinib) in combination with trastuzumab and pertuzumab as a chemotherapy-free maintenance treatment for adults with unresectable locally advanced or metastatic HER2-positive breast…
Pfizer: Previously Bearish, I'm Converting To A Cautious Bull (Rating Upgrade)
(PFE) Seeking Alpha - Pfizer’s stronger non-COVID outlook more than offsets lower COVID-19 revenue expectations, although full-year revenue guidance still implies a decline. - Pfizer expects another $2.7B in cost savings through 2029,…
My Top Dividend Stock to Buy in October Yields 6% and Cuts Shareholders a Monthly Check
10-year Treasury rates are at 5.28% at the time of this writing -- the highest level since 2002. In September, the Federal Reserve increased rates for the first time since 2023. And investors are concerned that further interest rate hikes…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
-
marketscreener.com411
-
tradingview.com328
-
finance.yahoo.com295
-
seekingalpha.com202
-
themarketsdaily.com199
Measured across the 4Conservative news index. Headline tone is a simple word-based reading of the latest 120 headlines, not a forecast.